Article Sidebar
Published:
Dec 13, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Comparing efficacy and safety of plasmapheresis versus atorvastatin in pathological progression of atherosclerosis in a rodent model
Abstract
Purpose: To evaluate the effect of plasmapheresis versus atorvastatin in pathological progression of atherosclerosis in a rodent model.
Method: A total of 90 male adult rats of up to 300 g were randomly distributed in three groups (n = 30): group 1 (plasmapheresis up to 1.5 ml daily); group 2 (atorvastatin 0.1 mg/kg per day), and group 3 (hypercholesteremic rats). The following variables were assessed for 24 weeks: plasma and hepatic lipid and anti-oxidant profiles; atherosclerotic abrasions/lesions; coronary atherosclerosis/coronary stenosis score (CSS), composition of atherosclerotic lesions, incidence of xanthoma, arch and thoracic surface involvement including arch and thoracic area occupied by lesion; and thoracic aorta (I/M) ratio.
Results: Compared to rats administered with atorvastatin, the rats treated with plasmapheresis had significantly greater improvement in levels of triglycerides (132 vs 124 mg/dl, p < 0.05), total cholesterol (201 vs 189 mg/dl, p < 0.05)), low-density lipoproteins (134 vs 123 mg/dl, p < 0.05)), very-low-density lipoprotein (11 vs 9 mg/dl, p < 0.05)) and high-density lipoprotein (36 vs 39 mg/dl, p < 0.05) levels. Plasmapheresis after 24 weeks of treatment improve CSS in all coronary arteries than atorvastatin (22 vs 24 respectively; p < 0.05. Furthermore, lesioned composition, I/M ratio and xanthoma incidence were significantly lower in plasmapheresis group than in atorvastatin group (p < 0.05).
Conclusion: Plasmapheresis is a better alternative than atorvastatin in preventing pathological progression of atherosclerosis.
